In vivo assessment of interictal sarcolemmal membrane properties in hypokalaemic and hyperkalaemic periodic paralysis.


Journal

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
ISSN: 1872-8952
Titre abrégé: Clin Neurophysiol
Pays: Netherlands
ID NLM: 100883319

Informations de publication

Date de publication:
04 2020
Historique:
received: 05 09 2019
revised: 26 11 2019
accepted: 10 12 2019
pubmed: 18 2 2020
medline: 19 12 2020
entrez: 18 2 2020
Statut: ppublish

Résumé

Hypokalaemic periodic paralysis (HypoPP) is caused by mutations of Ca MVRCs and responses to trains of stimuli were recorded in tibialis anterior and compared in patients with HyperPP(n = 7), HypoPP (n = 10), and normal controls (n = 26). Muscle relative refractory period was increased, and early supernormality reduced in HypoPP, consistent with depolarisation of the interictal resting membrane potential. In HyperPP the mean supernormality and residual supernormality to multiple conditioning stimuli were increased, consistent with increased inward sodium current and delayed repolarisation, predisposing to spontaneous myotonic discharges. The in vivo findings suggest the interictal resting membrane potential is depolarized in HypoPP, and mostly normal in HyperPP. The MVRC findings in HyperPP are consistent with presence of a window current, previously proposed on the basis of in vitro expression studies. Although clinically similar, HyperPP was electrophysiologically distinct from paramyotonia congenita. MVRCs provide important in vivo data that complements expression studies of ion channel mutations.

Identifiants

pubmed: 32066100
pii: S1388-2457(20)30028-6
doi: 10.1016/j.clinph.2019.12.414
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

816-827

Subventions

Organisme : NINDS NIH HHS
ID : R13 NS057995
Pays : United States
Organisme : NCRR NIH HHS
ID : U54 RR019498
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS059065
Pays : United States
Organisme : Medical Research Council
ID : MR/M01827X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0601943
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 209583/Z/17/Z
Pays : United Kingdom

Informations de copyright

Copyright © 2020 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Professor Hugh Bostock receives royalties from the sales of Qtrac Software used for the muscle excitability studies. The remaining authors have no conflicts of interest.

Auteurs

S Veronica Tan (SV)

MRC Centre for Neuromuscular Diseases, Queen Square, Institute of Neurology, UCL, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; Department of Neurology and Neurophysiology, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust and Department of Academic Neurosciences, Kings College London, UK. Electronic address: veronica.tan@gstt.nhs.uk.

Karen Suetterlin (K)

MRC Centre for Neuromuscular Diseases, Queen Square, Institute of Neurology, UCL, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

Roope Männikkö (R)

MRC Centre for Neuromuscular Diseases, Queen Square, Institute of Neurology, UCL, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

Emma Matthews (E)

MRC Centre for Neuromuscular Diseases, Queen Square, Institute of Neurology, UCL, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

Michael G Hanna (MG)

MRC Centre for Neuromuscular Diseases, Queen Square, Institute of Neurology, UCL, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

Hugh Bostock (H)

MRC Centre for Neuromuscular Diseases, Queen Square, Institute of Neurology, UCL, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH